Immune checkpoint inhibitor combination

This page covers all Immune checkpoint inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 and CTLA-4.

Targets

PD-1 and CTLA-4

Phase 3 pipeline (1)

• Neoadjuvant ipilimumab + nivolumab · The Netherlands Cancer Institute · Oncology
  This combination blocks two immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses before surgical resection.